Andere Sprachen BioXcel Therapeutics, Inc.

Aktien

A2JF20

US09075P1057

BTAI

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 28.05.2024			% 5 Tage	% 1. Jan.
1.86 ^USD	0.00%		-7.46%	-36.95%

09.05.	BioXcel Therapeutics, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI
09.05.	Transcript : BioXcel Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference	28.05.
BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology Annual Meeting	22.05.
BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting	21.05.
BioXcel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09.05.
BioXcel Therapeutics Reports First Quarter 2024 Financial Results	09.05.
BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024	25.04.
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting	24.04.
BioXcel Therapeutics to Launch At-Home Trial of Potential Bipolar, Schizophrenia Agitation Treatment	22.04.
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential	22.04.
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential	22.04.
BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia	10.04.
Bioxcel Therapeutics, Inc. Announces Transquility In-Care Pivotal Phase 3 Trial Plan with Bxcl501 for Agitation Associated with Alzheimer's Dementia	10.04.
BioXcel Therapeutics Prices $25 Million Registered Direct Offering of Shares, Warrants	25.03.
BioXcel Therapeutics Announces $25 Million Registered Direct Offering	25.03.
50 valores para invertir en IA, salud, movilidad y energía	25.03.
50 aandelen om te beleggen in KI, gezondheid, mobiliteit en energie	23.03.
50 titoli per investire in AI, salute, mobilità ed energia	22.03.
50 valeurs pour investir dans l'IA, la Santé, la Mobilité et l'Energie	22.03.
BioXcel Therapeutics Gets European Patent for Method of Treating Agitation in Dementia	15.03.
BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine	15.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen BioXcel Therapeutics, Inc.

Aktien

A2JF20

US09075P1057

BTAI

Andere Sprachen

Filter